Company: CRL
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001628280-25-052484
Chunk: 0

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U. S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company’s Audit Committee retained counsel to conduct an independent investigation into certain issues raised in the investigation.

On November 14, 2025, the SEC’s Division of Enforcement (Division) notified the Company that it concluded its investigation and, based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. Similarly, the Company’s independent investigation into these matters has also concluded, with no material findings.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                             CHARLES RIVER LABORATORIES INTERNATIONAL, INC.                   
  Date:      November 17, 2025      By:      /s/ Matthew L. Daniel                                            
                                             Matthew L. Daniel, Corporate Senior Vice President,              
                                             General Counsel, Corporate Secretary & Chief Compliance Officer